Mohammed Al Kanan: Early Identification of VTE Risk in Lung Cancer Patients
Mohammed Al Kanan, Director of Research and Studies at Ministry of Health Saudi Arabia, shared a post on LinkedIn about a recent article by Rong Deng et al. published in Frontiers in Molecular Biosciences, adding:
“Pleased to have contributed as a peer reviewer for a newly published original research article in Frontiers in Molecular Biosciences:
Construction and verification of a nomogram to predict the probability of venous thromboembolism in lung cancer patients.
This study tackles an important challenge in oncology: early identification of lung cancer patients at increased risk of venous thromboembolism (VTE) to support more individualized thromboprophylaxis and clinical decision-making.
Among 676 patients with lung cancer, the investigators developed a lung cancer–specific predictive nomogram incorporating clinically relevant factors such as acute infection, prolonged bed rest, D-dimer, adenocarcinoma, CEA, and COMPASS-CAT score.
What makes the findings particularly interesting is the model’s performance: AUC 0.894, outperforming several conventional VTE risk assessment tools, with favorable discrimination and calibration.
The work represents another step toward moving from generalized risk scores to more disease-specific and individualized prediction models—while prospective validation remains essential before widespread clinical implementation.
Grateful for the opportunity to contribute to the peer-review process and advancement of clinically relevant research.”
Title: Construction and verification of a nomogram to predict the probability of venous thromboembolism in lung cancer patients
Authors: Rong Deng, Jing Wu, Fei Tang, Yan Li, Qin Zhong, Ying Tong, Tingting Ni, Yu Zhang
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 6, 2026, 04:38M. Ibrahim Siddique: Does Routine Triple Therapy Pay Off After Anterior STEMI?
-
Sep 6, 2026, 04:29Sandra Revill Tremulis: The Lp(a)HORIZON Topline Results Raise Important Questions Beyond Simply ‘Does Lowering Lp(a) Work?’
-
Sep 5, 2026, 19:20Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
-
Sep 5, 2026, 19:18John R. Mehall: The Importance of Anticoagulation Management in ECMO
-
Sep 5, 2026, 19:16Thirunavukkarasu Angappan: Why Hemophilia B Still Needs Both Plasma-Derived and Recombinant Factor IX
-
Sep 5, 2026, 19:15Michelle Leona Cecil: Comprehensive Hemophilia Care Doesn’t Begin and End With One Appointment
-
Sep 5, 2026, 19:13Amparo Santamaria: Stem Cells and Hematology – Unlocking a New Frontier in Ovarian Regeneration
-
Sep 5, 2026, 19:10Strengthening the Public Health System for Blood Disorders – Hemophilia Federation of America
-
Sep 5, 2026, 19:08Deidra D. Harris: Supporting Hemophilia of Georgia and the Bleeding Disorders Community